These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15043143)

  • 21. Comparison of the RNase H cleavage kinetics and blood serum stability of the north-conformationally constrained and 2'-alkoxy modified oligonucleotides.
    Honcharenko D; Barman J; Varghese OP; Chattopadhyaya J
    Biochemistry; 2007 May; 46(19):5635-46. PubMed ID: 17411072
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective RNA cleavage by isolated RNase L activated with 2-5A antisense chimeric oligonucleotides.
    Silverman RH; Dong B; Maitra RK; Player MR; Torrence PF
    Methods Enzymol; 2000; 313():522-33. PubMed ID: 10595377
    [No Abstract]   [Full Text] [Related]  

  • 23. Rational selection of antisense oligonucleotide sequences.
    Smith L; Andersen KB; Hovgaard L; Jaroszewski JW
    Eur J Pharm Sci; 2000 Sep; 11(3):191-8. PubMed ID: 11042224
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Photodynamic antisense regulation using psoralen-conjugated oligo(nucleoside phosphorothioate)s (I). Growth regulation of cervical carcinoma cells.
    Iwase R; Yamayoshi A; Nishida J; Yamaoka T; Wake N; Murakami A
    Nucleic Acids Symp Ser; 1999; (42):223-4. PubMed ID: 10780460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of minimally modified antisense oligonucleotides for specific inhibition of gene expression.
    Uhlmann E; Peyman A; Ryte A; Schmidt A; Buddecke E
    Methods Enzymol; 2000; 313():268-84. PubMed ID: 10595361
    [No Abstract]   [Full Text] [Related]  

  • 26. Design of antisense and triplex-forming oligonucleotides.
    François JC; Lacoste J; Lacroix L; Mergny JL
    Methods Enzymol; 2000; 313():74-95. PubMed ID: 10595350
    [No Abstract]   [Full Text] [Related]  

  • 27. Oligonucleotides with 1,5-anhydrohexitol nucleoside building blocks: crystallization and preliminary X-ray studies of h(GTGTACAC).
    Declercq R; Van Aerschot A; Herdewijn P; Van Meervelt L
    Acta Crystallogr D Biol Crystallogr; 1999 Jan; 55(Pt 1):279-80. PubMed ID: 10089424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Translation of stable hepadnaviral mRNA cleavage fragments induced by the action of phosphorothioate-modified antisense oligodeoxynucleotides.
    Hasselblatt P; Hockenjos B; Thoma C; Blum HE; Offensperger WB
    Nucleic Acids Res; 2005; 33(1):114-25. PubMed ID: 15640448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antisense technologies. Improvement through novel chemical modifications.
    Kurreck J
    Eur J Biochem; 2003 Apr; 270(8):1628-44. PubMed ID: 12694176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA.
    Frieden M; Christensen SM; Mikkelsen ND; Rosenbohm C; Thrue CA; Westergaard M; Hansen HF; Ørum H; Koch T
    Nucleic Acids Res; 2003 Nov; 31(21):6365-72. PubMed ID: 14576324
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis of oligonucleotide inhibitors of DNA (Cytosine-C5) methyltransferase containing 5-azacytosine residues at specific sites.
    Güimil García R; Brank AS; Christman JK; Marquez VE; Eritja R
    Antisense Nucleic Acid Drug Dev; 2001 Dec; 11(6):369-78. PubMed ID: 11838638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis of high quality phosphorothioate oligonucleotides as antisense drugs. Use of I-linker in the elimination of 3'-terminal phosphorothioate monoesters.
    Ravikumar VT; Kumar RK; Capaldi DC; Cole DL
    Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):1421-5. PubMed ID: 14565433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determination of cellular internalization of fluoresceinated oligonucleotides.
    Benimetskaya L; Tonkinson J; Stein CA
    Methods Enzymol; 2000; 313():287-97. PubMed ID: 10595362
    [No Abstract]   [Full Text] [Related]  

  • 34. Characterization of therapeutic oligonucleotides using liquid chromatography with on-line mass spectrometry detection.
    Gilar M; Fountain KJ; Budman Y; Holyoke JL; Davoudi H; Gebler JC
    Oligonucleotides; 2003; 13(4):229-43. PubMed ID: 15000838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pseudo-cyclic oligonucleotides: in vitro and in vivo properties.
    Jiang Z; Kandimalla ER; Zhao Q; Shen LX; DeLuca A; Normano N; Ruskowski M; Agrawal S
    Bioorg Med Chem; 1999 Dec; 7(12):2727-35. PubMed ID: 10658577
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them?
    Eckstein F
    Antisense Nucleic Acid Drug Dev; 2000 Apr; 10(2):117-21. PubMed ID: 10805163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 2'-O,4'-C-ethylene-bridged nucleic acid (ENA) for effective antisense formation.
    Morita K; Yamate K; Kurakata S; Watanabe K; Imanishi T; Koizumi M
    Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):1619-21. PubMed ID: 14565480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stability of polycationic complexes of an antisense oligonucleotide in rat small intestine homogenates.
    González Ferreiro M; Crooke RM; Tillman L; Hardee G; Bodmeier R
    Eur J Pharm Biopharm; 2003 Jan; 55(1):19-26. PubMed ID: 12551700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toxicity and toxicokinetics of a phosphorothioate oligonucleotide against the c-myc oncogene in cynomolgus monkeys.
    Webb MS; Tortora N; Cremese M; Kozlowska H; Blaquiere M; Devine DV; Kornbrust DJ
    Antisense Nucleic Acid Drug Dev; 2001 Jun; 11(3):155-63. PubMed ID: 11446591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective degradation of targeted mRNAs using partially modified oligonucleotides.
    Dagle JM; Weeks DL
    Methods Enzymol; 2000; 313():420-36. PubMed ID: 10595370
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.